Bicycle Therapeutics to present Phase 1/2 BT5528 plus nivolumab study results at AACR 2026

Reuters

Mar 18

Bicycle <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to present Phase 1/2 BT5528 plus nivolumab study results at AACR 2026

Bicycle Therapeutics announced that results from a Phase 1/2 study of its EphA2-targeting Bicycle Drug Conjugate BT5528 in combination with nivolumab in patients with advanced solid tumors will be presented in a poster session at the AACR Annual Meeting 2026 on April 20. The company also said it will present future preclinical assessments of BT5528 anti-tumor activity in xenograft models of head and neck squamous cell carcinoma on April 19 and pancreatic ductal adenocarcinoma on April 21. In addition, a poster on EphA2 expression in muscle-invasive bladder cancer and its association with Nectin-4 and HER2 is scheduled for presentation on April 19. A separate poster describing development and first clinical experiences of an EphA2-specific PET imaging bicyclic peptide is slated for April 21.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260318186024) on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2620023751"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620023751\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620023751?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620023751","market":"nz","top_or_hot":-1,"title":"Bicycle Therapeutics to present Phase 1/2 BT5528 plus nivolumab study results at AACR 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bicycle <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to present Phase 1/2 BT5528 plus nivolumab study results at AACR 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bicycle Therapeutics announced that results from a Phase 1/2 study of its EphA2-targeting Bicycle Drug Conjugate BT5528 in combination with nivolumab in patients with advanced solid tumors will be presented in a poster session at the AACR Annual Meeting 2026 on April 20. The company also said it will present future preclinical assessments of BT5528 anti-tumor activity in xenograft models of head and neck squamous cell carcinoma on April 19 and pancreatic ductal adenocarcinoma on April 21. In addition, a poster on EphA2 expression in muscle-invasive bladder cancer and its association with Nectin-4 and HER2 is scheduled for presentation on April 19. A separate poster describing development and first clinical experiences of an EphA2-specific PET imaging bicyclic peptide is slated for April 21.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260318186024) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bicycle Therapeutics to present Phase 1/2 BT5528 plus nivolumab study results at AACR 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBicycle Therapeutics to present Phase 1/2 BT5528 plus nivolumab study results at AACR 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bicycle <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to present Phase 1/2 BT5528 plus nivolumab study results at AACR 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bicycle Therapeutics announced that results from a Phase 1/2 study of its EphA2-targeting Bicycle Drug Conjugate BT5528 in combination with nivolumab in patients with advanced solid tumors will be presented in a poster session at the AACR Annual Meeting 2026 on April 20. The company also said it will present future preclinical assessments of BT5528 anti-tumor activity in xenograft models of head and neck squamous cell carcinoma on April 19 and pancreatic ductal adenocarcinoma on April 21. In addition, a poster on EphA2 expression in muscle-invasive bladder cancer and its association with Nectin-4 and HER2 is scheduled for presentation on April 19. A separate poster describing development and first clinical experiences of an EphA2-specific PET imaging bicyclic peptide is slated for April 21.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260318186024) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL855sn4:1","article_id":"2620023751","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620023751","pubTimestamp":1773831636,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Bicycle Therapeutics announced that results from a Phase 1/2 study of its EphA2-targeting Bicycle Drug Conjugate BT5528 in combination with nivolumab in patients with advanced solid tumors will be presented in a poster session at the AACR Annual Meeting 2026 on April 20. The company also said it will present future preclinical assessments of BT5528 anti-tumor activity in xenograft models of head and neck squamous cell carcinoma on April 19 and pancreatic ductal adenocarcinoma on April 21. In addition, a poster on EphA2 expression in muscle-invasive bladder cancer and its association with Nectin-4 and HER2 is scheduled for presentation on April 19. A separate poster describing development and first clinical experiences of an EphA2-specific PET imaging bicyclic peptide is slated for April 21.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BCYC":"Bicycle Therapeutics Limited"},"translate_title":"Bicycle Therapeutics将在AACR 2026上展示1/2期BT5528加nivolumab研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCYC":0.9},"content_text":"Bicycle Therapeutics to present Phase 1/2 BT5528 plus nivolumab study results at AACR 2026\n    \n\n        Bicycle Therapeutics announced that results from a Phase 1/2 study of its EphA2-targeting Bicycle Drug Conjugate BT5528 in combination with nivolumab in patients with advanced solid tumors will be presented in a poster session at the AACR Annual Meeting 2026 on April 20. The company also said it will present future preclinical assessments of BT5528 anti-tumor activity in xenograft models of head and neck squamous cell carcinoma on April 19 and pancreatic ductal adenocarcinoma on April 21. In addition, a poster on EphA2 expression in muscle-invasive bladder cancer and its association with Nectin-4 and HER2 is scheduled for presentation on April 19. A separate poster describing development and first clinical experiences of an EphA2-specific PET imaging bicyclic peptide is slated for April 21.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260318186024) on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}